AFP and hepatocellular carcinoma: For early-stage HCC, annexin A2 also had a better diagnostic performance (AUROC 0.79, sensitivity 83.2%, and specificity 67.5%) compared with AFP (AUROC 0.73, sensitivity 54.7%, and specificity 81.3%), and the combination of annexin A2 with AFP improved the sensitivity and specificity up to 87.4 and 68.3% for early-stage HCC (144).